SNU-182 cells
Catalog #:
C0015003
Shipping advice:
Use only Express Delivery (overnight) for cell line. International shipping rate please contact us for details
| Frozen vial | USD450.0 |
Disease:
Carcinoma, hepatocellular; grade III/IV
Origin:
SNU-182 was derived in 1989 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Asian patient prior to cytotoxic therapy.
Species:
Homo sapiens, human
Liver
Epithelial
Adherent
aneuploid; modal number = 70
Male, 24 years of age, Asian
AddexBio-formulated RPMI-1640 Medium (C0004-01)
+ 10% FBS
Split sub-confluent cultures (70-80%) at a subcultivation ratio of 1:3 to 1:6 is recommended. Subculture at higher cell density is recommended. Culture at 5% CO2, 37°C.
Complete culture medium supplemented with 7.5% (v/v) DMSO II
Bacteria: Negative
Yeast: Negative
Mycoplasma: Negative
HIV: Negative
Hepatitis C: Negative
Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11,14
D16S539: 11,13
D5S818: 11,12
D7S820: 11
THO1: 9
TPOX: 8,11
vWA: 17
If use of this culture results in a scientific publication, it should be cited in the publication as: SNU-182 (AddexBio C0015003)
Tissue:
Morphology:
Properties:
Cytogenic data:
Patient:
Medium:
Subculture:
Freezing Medium:
Biosafety Level:
Sterility:
Pathogens:
DNA Profile (STR):
Citation Format:
References for SNU-182 cells:
1. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer. 1995;62(3):276-282. PMID: 7543080
